Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
178
resultados
Última actualización
28/08/2026 [07:44:00]
Resultados 150 a 175 de 178
Resumen de: US20260185159A1
0000 Among the various aspects of the present disclosure is the provision of a method of detecting, preventing, reversing, treating, or delaying the onset of a neurological disease (e.g., adult-onset neurological diseases, Alzheimer's disease, Parkinson's disease, Frontotemporal dementia).
Resumen de: US20260183333A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Resumen de: US20260185095A1
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
Resumen de: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Resumen de: WO2026142675A1
The invention relates to the development of an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: US20260183273A1
The invention relates to the therapeutic application of multifunctional compounds that act as α2 adrenoreceptor antagonists and cholinesterase inhibitors for the treatment of Alzheimer's disease and other neurodegenerative diseases, or the concomitant use of a mixture of an α2 adrenoreceptor antagonist and a cholinesterase inhibitor to achieve the same effect.
Resumen de: WO2026142672A1
The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: WO2026142674A1
The invention relates to the development of an active agent increasing the activity of a-carbonic anhydrase (hCA) enzymes, having the potential to be used in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: WO2026142673A1
The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: WO2026138307A1
New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.
Resumen de: WO2026139910A1
The invention relates to stable oral formulations of pimavanserin or its pharmaceutically acceptable salts, provided in the form of ready-to-use liquids, powders for reconstitution, orally dispersible tablets, and kits containing pre-measured powder and a liquid vehicle for reconstitution. These formulations are stable for longer periods and are palatable, thereby improving patient compliance and adherence in the treatment of psychosis associated with Parkinson's disease.
Resumen de: US20260183416A1
0000 A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.
Resumen de: US20260183276A1
0000 The subject invention pertains to compositions comprising Poly(A) RNA polymerase D5 (PAPD5) small molecule inhibitors and methods of using said compositions to treat Huntington's Disease (HD). The PAPD5 small molecule inhibitor is, for example, BCH001 and RG7834. The PAPD5 small molecule inhibitor can mitigate the neuronal defects and cell death in HD.
Resumen de: WO2025106603A1
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Resumen de: WO2025106878A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Resumen de: CN122121896A
The present disclosure relates to methods and compositions for the treatment of Parkinson's disease, which is a neurodegenerative disorder characterized by loss of dopaminergic neurons. In particular, the present disclosure provides formulations of dopaminergic cells that are demonstrated to have a therapeutic effect on motor and non-motor symptoms of the disease.
Resumen de: KR20260102258A
본 발명은 황기, 산수유, 당귀 및 오미자 추출물로 이루어진 생약복합 추출물을 유효성분으로 함유하는 파킨슨병의 예방, 개선 또는 치료용 조성물에 관한 것으로, 본 발명의 생약복합 추출물이 황기, 산수유, 당귀 및 오미자 단독 추출물에 비해 PC12 신경 세포에서 MPP+ 신경독성 처리 후 세포 보호 효과가 있고, 신경 세포의 활성산소종(reactive oxygen species, ROS) 생성을 억제시킬 뿐만 아니라, MPTP로 유도한 파킨슨병 동물모델에서 운동기능을 현저하게 향상시키는 효과가 있으므로, 파킨슨병의 예방 및 치료용 의약품 또는 파킨슨병의 예방 및 개선용 건강기능식품으로 유용하게 사용될 수 있다.
Resumen de: EP4768587A1
The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Resumen de: EP4512403A1
Described is a pharmaceutical composition comprising an antagonist/inhibitor of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a mood disorder/affective disorder and/or chronic stress and/or anxiety disorders and/or Parkinson's disease. Moreover, described is a pharmaceutical composition comprising an agonist/activator of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a bipolar affective disorder (ICD-10 F31) during the manic phase, appetitive disorders, preferably anorexia or bulimia. Further, described is a method for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or an agonist/activator of NPBWR1.
Resumen de: EP4768479A1
Compounds represented by the following structure, or tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs thereof. Said compounds can be used as AT2R agonists.
Resumen de: EP4768503A1
Provided is an antibody or an antigen-binding fragment thereof that binds to β-Amyloid (Aβ). Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment thereof or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Resumen de: CN122297482A
The invention discloses application of bimatoprost in preparation of a medicine for preventing and/or treating Parkinson's disease in the field of medicine reutilization. Bimatoprost is a prostaglandin F2alpha analogue, and is mainly used for glaucoma and eyelash growth at present. Researches find that bimatoprost can improve behavior disorders related to the Parkinson's disease, improve expression of melanin dopaminergic neuron related protein tyrosine hydroxylase and reduce abnormal accumulation of alpha-synuclein, and has good improvement and protection effects on the Parkinson's disease. The invention provides a new drug choice for treatment of Parkinson's disease.
Resumen de: CN122297678A
The invention relates to application of STBD1 as a target spot in treatment of Alzheimer's disease. Specifically, the invention relates to application of a reagent targeting STBD1 in preparation of drugs for treating Alzheimer's disease, and the reagent targeting STBD1 is selected from: i) a reagent for inhibiting and/or reducing the expression level of STBD1 gene and/or protein; and ii) an interference agent for the interaction of STBD1 with GABARAPL1.
Resumen de: CN122297525A
The invention discloses application of maggot oil in preparation of medicines for preventing and/or treating neurodegenerative diseases, and belongs to the technical field of biological medicines. The maggot oil disclosed by the invention is prepared by adopting supercritical CO2 extraction, the content of EPA (eicosapentaenoic acid) is 2.16 g/100g, the content of nervonic acid is 0.0104 g/100g, and the total amount of unsaturated fatty acid reaches 49.1 g/100g. The maggot oil can play a nerve protection role by inhibiting beta-amyloid protein deposition, reducing neuronal apoptosis, relieving neuroinflammation, protecting dopaminergic neurons and other pathways, and can effectively resist neuron damage caused by excitatory toxicity and oxidative stress, remarkably improve spatial learning and memory ability and relieve cognitive function decline. The invention provides an efficient and safe drug choice for prevention and treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and the like.
Nº publicación: CN122297714A 30/06/2026
Solicitante:
OUJIANG LABORATORY
\u74EF\u6C5F\u5B9E\u9A8C\u5BA4
Resumen de: CN122297714A
The invention discloses a preparation method and application of a drug-loaded fibroin preparation crossing a blood brain barrier, and relates to the technical field of biomedical materials. In order to regulate and control self-assembly of bioactive particles by using silk protein fibers, the performance of a nano delivery system is optimized, and the application value of the nano delivery system in the field of treatment of various diseases such as the Alzheimer's disease is improved. The silk protein nano-carrier specifically comprises silk protein nano-fibers, functional treatment active components and mannose/rabies virus capsid protein, the silk protein nano-fibers form nano-particles through self-assembly, and the functional treatment active components are prepared into the bioactive silk protein nano-carrier through the silk protein nano-fiber self-assembly process. The preparation method is simple in process and convenient to operate, the formed stable drug-loaded fibroin nano-delivery carrier preparation is combined with different receptors of brain microvascular endothelial cells to realize high brain entering efficiency, and a brand new thought is provided for design of the fibroin nano-delivery carrier.
BOPI
Sede Electrónica
